$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Detailed explanation of the efficacy and possible risks of ixazomib
2026-02-01 22:25:32
Check Details
Indications and usage guidelines for ixazomib in the treatment of multiple myeloma
2026-02-01 22:25:32
Check Details
New drug purchasing guide for ixazomib in 2024
2026-02-01 22:25:32
Check Details
Instructions for use of the Lao version of Sparsentan
2026-02-01 22:25:32
Check Details
The principle of action of sparsentane and its application in the treatment of kidney disease
2026-02-01 22:25:32
Check Details
Overview of Potential Adverse Reactions of Sparsentan Medications
2026-02-01 22:25:32
Check Details
Sparsentan Drug Prices in 2024
2026-02-01 22:25:32
Check Details
Dietary and behavioral guidelines while using Sparsentan
2026-02-01 22:25:32
Check Details
What kind of medicine is Lynparza? What's the price?
2026-02-01 22:25:32
Check Details
Detailed instructions for Lynparza (Lipdrox), usage and dosage, side effects
2026-02-01 22:25:32
Check Details
Which company makes Lynparza (Lipdroxy) and what is it used for?
2026-02-01 22:25:32
Check Details
A new chapter in ovarian cancer treatment with Lynparza
2026-02-01 22:25:32
Check Details
1
2
...
842
843
844
845
846
847
848
...
10238
10239
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Vosoritide Storage and Reconstitution: Refrigerate, 90-Day Room Temp, Use Within 3 Hours
2
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
3
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
4
Vosoritide Side Effects and Pre-Injection Food/Fluid: Injection-Site Reactions, Transient Hypotension
5
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
6
Pretomanid Mechanism and BPaL Use in Drug-Resistant TB
7
Pacritinib Drug Contraindications and Precautions
8
Pomalidomide Side Effects, Risk Monitoring, and Precautions
9
Dasatinib for Ph+ Chronic Myeloid Leukemia: Dosage, Administration, and Long-Term Care
10
Obeticholic Acid 5 mg for PBC: Dosage, Risks, and Current Status
11
Acalabrutinib Monotherapy for CLL: What It Can and Cannot Do
12
Bepirovirsen for Chronic HBV Functional Cure: FDA Criteria and B-Well Data